Status:
COMPLETED
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
Lead Sponsor:
Gennaro Sardella
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Dual antiplatelet therapy with aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug e...
Eligibility Criteria
Inclusion
- patients underwent to PCI
- lopidogrel resistance after Platelet reactivity blood test
Exclusion
- history of bleeding diathesis
- chronic oral anticoagulation treatment
- contraindications to antiplatelet therapy
- PCI or coronary artery bypass grafting (CABG) \<3 months
- hemodynamic instability
- platelet count \<100,000/μl
- hematocrit \<30%
- creatinine clearance \<25 ml/min
- Patients with a history of stroke
- contraindication for prasugrel administration
- patients weighing \<60 kg
- \>75 years of age.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01465828
Start Date
October 1 2011
End Date
January 1 2012
Last Update
March 27 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept.of Cardiovascular Sciences,Policlinico Umberto I
Roma, Roma, Italy, 00161
2
Dept.of Cardiovascular Sciences,Policlinico Umberto I
Rome, Rome, Italy, 00155